Clinical Trials Browser

NETWORK × Lung Neoplasms × pembrolizumab × Clear all

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05633602 2026-04-17

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04093167 2026-03-11

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Phase 2/3 Recruiting

Lung Neoplasms

NCT03971474 2024-09-03

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Phase 2 Completed

166 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms